Literature DB >> 7853976

Increased length of hospital stay due to Clostridium difficile associated diarrhoea.

T V Riley, J P Codde, I L Rouse.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7853976     DOI： 10.1016/s0140-6736(95)90439-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  15 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital.

Authors:  Alan J Forster; Monica Taljaard; Natalie Oake; Kumanan Wilson; Virginia Roth; Carl van Walraven
Journal:  CMAJ       Date:  2011-12-05       Impact factor: 8.262

Review 3.  Antibiotic-associated diarrhoea. A costly problem.

Authors:  T V Riley
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

4.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

5.  Clostridium difficile: a pathogen of the nineties.

Authors:  T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

6.  Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.

Authors:  Gregory J Babcock; Teresa J Broering; Hector J Hernandez; Robert B Mandell; Katherine Donahue; Naomi Boatright; Anne M Stack; Israel Lowy; Robert Graziano; Deborah Molrine; Donna M Ambrosino; William D Thomas
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

7.  Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries.

Authors:  Christian Eckmann; Matthew Wasserman; Faisal Latif; Graeme Roberts; Axelle Beriot-Mathiot
Journal:  Eur J Health Econ       Date:  2013-10

8.  Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.

Authors:  D Pavliakova; J S Moncrief; D M Lyerly; G Schiffman; D A Bryla; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  N-CDAD in Canada: results of the Canadian Nosocomial Infection Surveillance Program 1997 N-CDAD Prevalence Surveillance Project.

Authors:  M Hyland; M Ofner-Agostini; M Miller; S Paton; M Gourdeau; M Ishak
Journal:  Can J Infect Dis       Date:  2001-03

10.  Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator.

Authors:  Glen P Carter; Dena Lyras; David L Allen; Kate E Mackin; Pauline M Howarth; Jennifer R O'Connor; Julian I Rood
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.